Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;11(9):e989.
doi: 10.1002/iid3.989.

Insights on Covid-19 with superimposed pulmonary histoplasmosis: The possible nexus

Yahya A Almutawif  1 , Hayder M Al-Kuraishy  2 , Ali I Al-Gareeb  2 , Athanasios Alexiou  3   4 , Marios Papadakis  5 , Hamza M A Eid  1 , Hebatallah M Saad  6 , Gaber El-Saber Batiha  7
Affiliations
Review

Insights on Covid-19 with superimposed pulmonary histoplasmosis: The possible nexus

Yahya A Almutawif et al. Immun Inflamm Dis. 2023 Sep.

Abstract

A novel coronavirus (CoV) known as severe acute respiratory syndrome CoV type 2 is the causative agent for the development of CoV disease 2019 (Covid-19). Covid-19 may increase the risk of developing pulmonary histoplasmosis due to immune dysregulation. In addition, Covid-19 may enhance the propagation of acute pulmonary histoplasmosis due to lung injury and inflammation, and using corticosteroids in severely affected Covid-19 patients may reactivate latent pulmonary histoplasmosis. Likewise, activation of inflammatory signaling pathways during H. capsulatum infection may increase the severity of Covid-19 and vice versa. Furthermore, lymphopenia in Covid-19 may increase the risk for the progress of pulmonary histoplasmosis besides activation of inflammatory signaling pathways during H. capsulatum infection may increase the severity of Covid-19 and vice versa. Therefore, this critical review aimed to find the potential link between Covid-19 pneumonia and pulmonary histoplasmosis concerning the immunological response.

Keywords: Covid-19; inflammatory signaling pathways; pulmonary histoplasmosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Pulmonary histoplasmosis and immune response.
Figure 2
Figure 2
Covid‐19 and immune response.
Figure 3
Figure 3
The inflammatory signaling in Covid‐19 and pulmonary histoplasmosis.
See this image and copyright information in PMC

References

    1. Al‐Kuraishy HM, Al‐Gareeb AI, Alzahrani KJ, Cruz‐Martins N, Batiha GE‐S. The potential role of neopterin in Covid‐19: a new perspective. Mol Cell Biochem. 2021;476(11):4161‐4166. - PMC - PubMed
    1. McFee DRB. COVID‐19 medical management including World Health Organization (WHO) suggested management strategies. Dis Mon. 2020;66(9):101068. - PMC - PubMed
    1. Al‐Kuraishy HM, Al‐Gareeb AI, Alzahrani KJ, Alexiou A, Batiha GE‐S. Niclosamide for Covid‐19: bridging the gap. Mol Biol Rep. 2021;48(12):8195‐8202. - PMC - PubMed
    1. Onohuean H, Al‐Kuraishy HM, Al‐Gareeb AI, Qusti S, Alshammari EM, Batiha GE‐S. Covid‐19 and development of heart failure: mystery and truth. Naunyn‐Schmiedeberg's Arch Pharmacol. 2021;394(10):2013‐2021. - PMC - PubMed
    1. Al‐kuraishy HM, Al‐Gareeb AI, Kaushik A, Kujawska M, Batiha GES. Ginkgo biloba in the management of the COVID‐19 severity. Arch Pharm. 2022;355(10):e2200188. 10.1002/ardp.202200188 - DOI - PMC - PubMed

Publication types